- Company
- Next Biomedical seeks IPO…knocks on global GI mkt
- by Hwang, Byung-woo Aug 2, 2024 05:52am
- Next Biomedical will seek KOSDAQ listing in August based on its achievements in the GI field. The company has been collaborating with the global company Medtronic to expand into the endoscopic hemostatic agent market with its flagship product. Based on the revenue growth, the company plans to establish the drug as a standard-of-care in the gl
- Company
- Mounjaro bids into Korea's obesity treatment market
- by Hwang, Byung-woo Aug 2, 2024 05:51am
- Lilly Korea announced on the 1st that its GIP/GLP-1 dual-acting agent, Mounjaro (tirzepatide), has received approval from the Ministry of Food and Drug Safety (MFDS) as an adjunct for chronic weight management. Mounjaro is the first and, to date, the only (as of July 2024) GIP/GLP-1 dual receptor agonist available. It selectively binds to
- Company
- New oHCM drug 'Camzyos' is under review for reimb list
- by Eo, Yun-Ho Aug 2, 2024 05:51am
- The new drug for obstructive hypertrophic cardiomyopathy (oHCM), 'Camzyos,' has entered the last stage for reimbursement listing. Sources said that the Ministry of Health and Welfare (MOHW) ordered the National Health Insurance Service (NHIS) to initiate a drug price negotiation for Bristol Myers Squibb Korea's Camzyos (mavacamten), a tre
- Company
- VUNO knocks on the U.S. market to generate operating profit
- by Hwang, Byung-woo Aug 1, 2024 05:48am
- Medical artificial intelligence (AI) company VUNO has launched an AI-based brain quantification device in the United States market. Whether the company will use this as a stepping stone for sales expansion garners attention. VUNO's strategy is to quickly turn around by increasing the sales performance of its major product and entering the ove
- Company
- Celltrion’s Steqeyma approved in CAN…targets Stelara mkt
- by Hwang, Byung-woo Aug 1, 2024 05:48am
- On the 31st, Celltrion announced that it had received New Drug Application (NDS) approval for its Stelara biosimilar Steqeyma from Health Canada. With the approval, Celltrion may now sell Steqeyma in Canada for plaque psoriasis, psoriatic arthritis, and Crohn's disease. The Canadian approval supports the company’s plan to settle in
- Company
- Will the cardiomyopathy drug Vyndamax be reimb this time?
- by Eo, Yun-Ho Aug 1, 2024 05:48am
- The reimbursement listing process for ‘Vyndamax,’ Pfizer’s treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), is gaining attention in Korea. According to industry sources, discussions for the reimbursement of Pfizer Korea’s Vyndamax (tafamidis 61mg) for Transthyretin amyloid&160;cardiomyopathy (ATTR-CM) have again begun.
- Opinion
- [Reporter’s View] More legislation needed for CSO reporting
- by Lee, Jeong-Hwan Aug 1, 2024 05:48am
- The enforcement of the Pharmaceutical Affairs Act, which requires Contract Sales Organizations (CSOs) to report to local governments and educate their employees on the prohibition of rebates, is now 2 months away. The pharmaceutical and CSO industries are hoping the implementation of the reporting system will serve as a milestone to incre
- Company
- Kim Sang-pyo, appointed as Moderna Korea's new GM
- by Eo, Yun-Ho Aug 1, 2024 05:47am
- Moderna Korea appointed Kim Sang-pyo, the former head of AstraZeneca Korea, as the new General Manager. Moderna announced the appointment of Kim Sang-pyo as the new General Manager, effective on August 1st. Kim will head Moderna's subsidiary in South Korea, succeeding Sohn Ji-young, who led the company's establishment in the Korean marke
- Company
- Combination cancer immunotherapies show high synergy
- by Son, Hyung-Min Aug 1, 2024 05:47am
- Data demonstrating the effectiveness of the combination of cancer immunotherapies are being disclosed. Recently, Opdivo+Yerboy therapy has been shown to improve the survival duration when used as a first-line treatment of hepatocellular carcinoma (HCC). GI Innovation confirmed partial response (PR) using cancer immunotherapies as combination the
- Company
- Commercialization of global RSV vaccines in progress in KOR
- by Son, Hyung-Min Jul 31, 2024 05:52am
- A global respiratory syncytial virus (RSV) vaccine has entered late-stage clinical trials for the first time in Korea, testing its potential for commercialization. Pfizer recently received approval to initiate a Phase III clinical trial in Korea to evaluate the immunogenicity of its RSV vaccine. Moderna is applying for Japanese approval of its R
